After a period of weight loss, the scale may stay around the same number for a while. This can feel unsettling when you expected further change. A pause does not by itself prove treatment failure or personal failure. A structured review of the pattern is more useful.
Health information for general guidance. This content provides general information. It does not replace medical advice, examination, diagnosis or treatment, or individual nutrition advice. Discuss medication decisions with your treating clinician; do not change treatment based on this page. Seek medical help for acute or severe symptoms.
Describe the observation first
How long has weight seemed stable, and how was it measured? Different scales, times, clothing and fluid balance affect comparisons. Constipation or illness can also produce short-term changes. Use existing records rather than responding by weighing constantly. Describe whether the pattern has actually remained similar for a sustained period. You do not need to diagnose the plateau yourself; a clear account gives your clinician a useful starting point. Add context without trying to explain every individual fluctuation.
Match expectations to a real course
Weight change is not equally steady or equally large for everyone. Trial averages are not a personal target. After weight loss, the starting conditions for further planning have changed too. Stable weight may be a meaningful result depending on previous progress and health goals. This does not mean dismissing every unexpected development. Ask how you will judge effect, tolerance and overall benefit together, and what review period makes sense for your particular treatment rather than applying somebody else’s online timetable.
Review daily life without blame
Have meals, sleep, activity, symptoms or circumstances changed? Are there difficulties following the prescribed regimen, paying for treatment or obtaining supplies? These questions aim to find solutions, not test your willpower. A brief record of a few typical days may help. Avoid responding to frustration by removing more and more foods or eating extremely little. Care should also consider strength, adequate nutrition and quality of life. Severe restriction can work against those goals without explaining the underlying issue.
Prepare a focused clinical discussion
Bring your weight record, current medicines, relevant symptoms and key questions. Ask which other causes or factors deserve assessment and whether agreed goals still fit. Your clinician can review the particular prescription and possible alternatives. Do not increase doses, shorten intervals or combine products based on online advice. Stopping or switching also needs an agreed plan; a plateau alone cannot provide safe instructions. Mention practical barriers openly so the discussion addresses the treatment you are actually able to follow.
Agree a next step you can review
Choose a realistic adjustment or observation and arrange a follow-up point. This may mean nutrition support, assessment of symptoms or a more workable activity routine. Include goals such as getting up more easily, improved stamina or clinically relevant measurements where appropriate. New severe symptoms, marked weakness or very rapid unintended changes need timely assessment independently of a plateau. A useful plan asks not only whether weight falls, but also how you are doing along the way. Progress should remain understandable and connected to your health.
Three points for your appointment
- Describe the time period and conditions of your measurements.
- Note changes in food, activity, symptoms and prescribed use.
- Choose one health goal alongside the number on the scale.
Common questions
Should I immediately eat less during a plateau?
Not automatically. Review the pattern, nutritional intake and symptoms first. If you already eat very little or are becoming weaker, further restriction may be inappropriate.
Does a plateau mean I must change medication?
No. Decisions depend on the product, course, tolerance, medical conditions and goals. A period of stable scale readings cannot decide this alone.
Sources & further reading
- European Medicines Agency: Wegovy – EPAR and product information
- European Medicines Agency: Mounjaro – EPAR and product information
- Nutritional priorities to support GLP-1 therapy for obesity: joint advisory
- WHO: GLP-1 medicines in treating obesity
Sources checked:





Questions and experiences
Share a question or a useful experience about this topic. Every contribution is checked before publication. Comments may be written in different languages.
Loading reader contributions…
Opening the form sets a necessary session cookie. No email address is required. Publication is subject to moderation and is not guaranteed. For deletion requests: Contact